Larimar Therapeutics, Inc.

Listed Company

LRMRCIK 0001374690NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-165.70M

Total Assets

$145.84M

Equity

$78.08M

Shares Out

103.88M

Op. Cash Flow

$-113.20M

Business

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company developing treatments for complex rare diseases using a proprietary cell penetrating peptide (CPP) platform. Its main product candidate is nomlabofusp, a subcutaneously administered recombinant fusion protein designed to deliver tissue frataxin to mitochondria for Friedreich’s ataxia. The company’s activities are organized around drug discovery and platform development, clinical development programs (Phase 1–2 and open-label studies), manufacturing partnerships and intellectual property/licensing. Larimar focuses on global regulatory and commercialization efforts in the United States, European Union, United Kingdom, Canada, Australia and other jurisdictions, utilizing clinical trial networks and third-party manufacturing and potential commercialization partners.

Summary from filing dated 2025-03-24

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	154	73	28	24	38
General and administrative	18	18	14	12	12
Total operating expenses	172	91	42	37	50
Loss from operations	−172	−91	−42	−37	−50
Other income, net	7	10	5	1	−171,000
Net loss	−166	−81	−37	−35	−51
Unrealized gain (loss) on marketable securities	−94,000	67,000	112,000	−31,000	−1,000
Total other comprehensive gain (loss)	−94,000	67,000	112,000	−31,000	−1,000
Total comprehensive loss	−166	−81	−37	−35	−51

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	85	33	27	27	70
Short-term marketable securities	51	150	60	92	—
Prepaid expenses and other current assets	5	12	3	2	2
Total current assets	142	195	90	121	72
Property and equipment, net	622,000	881,000	684,000	831,000	1
Operating lease right-of-use assets	2	3	3	3	3
Restricted cash	606,000	606,000	1	1	1
Other assets	523,000	596,000	659,000	638,000	669,000
Total assets	146	200	96	126	79
Accounts payable	5	2	1	2	2
Accrued expenses	58	21	7	8	7
Operating lease liabilities, current	1	1	837,000	611,000	594,000
Total current liabilities	65	24	10	11	9
Operating lease liabilities	3	4	5	5	5
Total liabilities	68	28	14	16	14
Commitments and contingencies (See Note 8)	—	—	—	—	—
Preferred stock; $0.001 par value per share; 5,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 250,000 and no shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	—	—	—	—	—
Common stock, $0.001 par value per share; 115,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 83,090,392 and 63,815,065 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	83,000	64,000	43,000	43,000	18,000
Additional paid-in capital	513	441	270	262	181
Accumulated deficit	−435	−269	−189	−152	−116
Accumulated other comprehensive gain	54,000	148,000	81,000	−31,000	—
Total stockholders' equity	78	172	82	111	64
Total liabilities and stockholders' equity	146	200	96	126	79

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−166	−81	−37	−35	−51
Stock-based compensation expense	7	9	8	7	5
Lease expense	−281,000	−189,000	−82,000	−46,000	—
Depreciation expense	350,000	318,000	311,000	318,000	326,000
Amortization of premium on marketable securities	−2	−5	−2	−774,000	−14,000
Prepaid expenses and other current assets	7	−8	−1	−204,000	3
Accounts payable	3	1	−403,000	26,000	−974,000
Accrued expenses	38	13	−1	2	749,000
Other assets	73,000	63,000	−21,000	31,000	−250,000
Net cash used in operating activities	−113	−71	−34	−28	−42
Purchases of property and equipment	−91,000	−515,000	−164,000	−100,000	−333,000
Purchases of marketable securities	−84	−228	−101	−134	−8
Maturities of marketable securities	184	143	—	—	—
Net cash provided by (used in) investing activities	100	−85	33	−91	24
Proceeds from issuance of common stock, net of issuance costs	65	162	—	75	20
Proceeds from exercise of stock options and warrants	—	77,000	30,000	—	—
Net cash provided by financing activities	65	162	30,000	75	20
Net increase in cash, cash equivalents and restricted cash	52	6	−76,000	−43	2
Offering costs included in accounts payable and accrued expense	100,000	50,000	—	—	—
Leased assets obtained in exchange for new operating lease liabilities	—	465,000	790,000	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro